You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Bharat Biotech says higher pricing of Covaxin required in private markets

Fundamental business reasons ranging from low procurement volumes, high distribution costs and retail margins among few others contribute to higher pricing of Covaxin, Bharat Biotech said

Topics
Coronavirus | Coronavirus Vaccine | Bharat Biotech

BS Web Team & Agencies  |  New Delhi 

Bharat Biotech, Covaxin
Photo: Shutterstock

on Tuesday justified the higher pricing of its vaccine in the private market, saying the supply price of the shot for Government of India is clearly not sustainable in the long run.

"The supply price of Covaxin to Govt of India at Rs 150 a dose, is a non-competitive price and clearly not sustainable in the long run," the Hyderabad-based vaccine maker has said.

"Hence a higher price in private market is required to offset part of the costs," it said. is currently supplying the vaccine for Centre at Rs 150 a dose.

Fundamental business reasons ranging from low procurement volumes, high distribution costs and retail margins among few others contribute to higher pricing of Covaxin, said justifying the higher price when compared to other Covid-19 vaccines available for the private sector in India.

"Unlike most medicines and therapeutics, vaccines are provided free of cost by the Govt of India to all eligible Indian citizens. Thus, the procurement of vaccines by private hospitals is optional and not mandatory, albeit it gives a choice to citizens who are willing to pay for better convenience. In our view, the question of product pricing is only of extraneous interest to all concerned, especially when the same vaccine is made available free of cost."

Bharat Biotech has so far invested over Rs 500 crore at risk from its own resources for product development, clinical trials and setting up of manufacturing facilities for Covaxin, it added.

The government has set the maximum price private hospitals can charge for the Covaxin at Rs 1,410. The Centre has placed advance orders for 190 million Covaxin doses to be supplied between August and December.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, June 15 2021. 14:27 IST
RECOMMENDED FOR YOU